Avadel Pharmaceuticals PLC (AVDL) Fundamental Analysis & Valuation

NASDAQ:AVDL • IE00BDGMC594

Current stock price

21.64 USD
+0.01 (+0.05%)
At close:
21.65 USD
+0.01 (+0.05%)
After Hours:

This AVDL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AVDL Profitability Analysis

1.1 Basic Checks

  • AVDL had negative earnings in the past year.
  • AVDL had a positive operating cash flow in the past year.
  • AVDL had negative earnings in 4 of the past 5 years.
  • AVDL had a negative operating cash flow in each of the past 5 years.
AVDL Yearly Net Income VS EBIT VS OCF VS FCFAVDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

  • The Return On Assets of AVDL (-0.14%) is better than 77.49% of its industry peers.
  • Looking at the Return On Equity, with a value of -0.28%, AVDL is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
Industry RankSector Rank
ROA -0.14%
ROE -0.28%
ROIC N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVDL Yearly ROA, ROE, ROICAVDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • With an excellent Gross Margin value of 91.09%, AVDL belongs to the best of the industry, outperforming 92.67% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AVDL has grown nicely.
  • The Profit Margin and Operating Margin are not available for AVDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
AVDL Yearly Profit, Operating, Gross MarginsAVDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. AVDL Health Analysis

2.1 Basic Checks

  • AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AVDL has been increased compared to 1 year ago.
  • The number of shares outstanding for AVDL has been increased compared to 5 years ago.
  • The debt/assets ratio for AVDL is higher compared to a year ago.
AVDL Yearly Shares OutstandingAVDL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVDL Yearly Total Debt VS Total AssetsAVDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 7.90 indicates that AVDL is not in any danger for bankruptcy at the moment.
  • AVDL has a better Altman-Z score (7.90) than 81.15% of its industry peers.
  • The Debt to FCF ratio of AVDL is 1.80, which is an excellent value as it means it would take AVDL, only 1.80 years of fcf income to pay off all of its debts.
  • AVDL has a Debt to FCF ratio of 1.80. This is amongst the best in the industry. AVDL outperforms 95.29% of its industry peers.
  • AVDL has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.35, AVDL perfoms like the industry average, outperforming 40.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.8
Altman-Z 7.9
ROIC/WACCN/A
WACC7.87%
AVDL Yearly LT Debt VS Equity VS FCFAVDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • A Current Ratio of 2.76 indicates that AVDL has no problem at all paying its short term obligations.
  • AVDL has a Current ratio (2.76) which is comparable to the rest of the industry.
  • AVDL has a Quick Ratio of 2.37. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AVDL (2.37) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.37
AVDL Yearly Current Assets VS Current LiabilitesAVDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. AVDL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 100.00% over the past year.
  • The Revenue has grown by 79.88% in the past year. This is a very strong growth!
  • The Revenue has been growing by 23.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%

3.2 Future

  • The Earnings Per Share is expected to grow by 39.72% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 24.44% on average over the next years. This is a very strong growth
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y39.72%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y24.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
AVDL Yearly Revenue VS EstimatesAVDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
AVDL Yearly EPS VS EstimatesAVDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

4

4. AVDL Valuation Analysis

4.1 Price/Earnings Ratio

  • AVDL is valuated quite expensively with a Price/Forward Earnings ratio of 26.23.
  • AVDL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AVDL is cheaper than 73.82% of the companies in the same industry.
  • AVDL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 38.50.
Industry RankSector Rank
PE N/A
Fwd PE 26.23
AVDL Price Earnings VS Forward Price EarningsAVDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 76.44% of the companies in the same industry are more expensive than AVDL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 101.28
EV/EBITDA N/A
AVDL Per share dataAVDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as AVDL's earnings are expected to grow with 64.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.39%
EPS Next 3Y64.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVDL Dividend Analysis

5.1 Amount

  • AVDL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVDL Fundamentals: All Metrics, Ratios and Statistics

Avadel Pharmaceuticals PLC

NASDAQ:AVDL (2/11/2026, 8:07:16 PM)

After market: 21.65 +0.01 (+0.05%)

21.64

+0.01 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-09
Inst Owners95.18%
Inst Owner Change-0.1%
Ins Owners1.06%
Ins Owner Change-15.72%
Market Cap1.96B
Revenue(TTM)248.52M
Net Income(TTM)-278.00K
Analysts70
Price Target21.48 (-0.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.03%
Min EPS beat(2)-100%
Max EPS beat(2)258.07%
EPS beat(4)2
Avg EPS beat(4)42.28%
Min EPS beat(4)-100%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)22.06%
EPS beat(12)4
Avg EPS beat(12)-2.88%
EPS beat(16)5
Avg EPS beat(16)-12.25%
Revenue beat(2)2
Avg Revenue beat(2)5.92%
Min Revenue beat(2)3.23%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)3.03%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.63%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.23
P/S 7.89
P/FCF 101.28
P/OCF 56.74
P/B 19.96
P/tB 24.08
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.83
Fwd EY3.81%
FCF(TTM)0.21
FCFY0.99%
OCF(TTM)0.38
OCFY1.76%
SpS2.74
BVpS1.08
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.14%
ROE -0.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.09%
FCFM 7.79%
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.8
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.76
Quick Ratio 2.37
Altman-Z 7.9
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y39.72%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y24.44%
EBIT growth 1Y92.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.2%
EBIT Next 3Y69.86%
EBIT Next 5Y44.48%
FCF growth 1Y116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.82%
OCF growth 3YN/A
OCF growth 5YN/A

Avadel Pharmaceuticals PLC / AVDL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Avadel Pharmaceuticals PLC?

ChartMill assigns a fundamental rating of 5 / 10 to AVDL.


What is the valuation status for AVDL stock?

ChartMill assigns a valuation rating of 4 / 10 to Avadel Pharmaceuticals PLC (AVDL). This can be considered as Fairly Valued.


Can you provide the profitability details for Avadel Pharmaceuticals PLC?

Avadel Pharmaceuticals PLC (AVDL) has a profitability rating of 3 / 10.


What is the financial health of Avadel Pharmaceuticals PLC (AVDL) stock?

The financial health rating of Avadel Pharmaceuticals PLC (AVDL) is 7 / 10.